Display Settings:


Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Rheum Dis Clin North Am. 2009 May;35(2):359-72. doi: 10.1016/j.rdc.2009.06.007.

Pharmacotherapy of fibromyalgia.

Author information

  • 1Seattle Rheumatology Associates, Swedish Medical Center, Seattle, WA 98104, USA.pmease@nwlink.com


Advances have occurred in the pharmacotherapy of fibromyalgia (FM) and the methodology of clinical trial design in FM in parallel with improved understanding of the underlying pathophysiologic mechanisms. Several medications have been approved for the management of FM based on their clinically meaningful and durable effect on pain in monotherapy trials and their beneficial effect on patients'global impression of change, function, and other key symptom domains such as fatigue, sleep disturbance, and cognition. Adjunctive therapy with medicines targeted to specific symptom domains such as sleep as well as treatments aimed toward common comorbid conditions such as irritable bowel syndrome or disease states such as rheumatoid arthritis should be considered for the purpose of reducing the patient's overall symptom burden.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk